

REPORTING Norway 2018											Date for publication:	30/06/2019
Full name (Art. 1.01)	HCPs: City of Principal Practice HCOs: city where registered (Art. 3)	Country of Principal Practice Schedule 1)	Principal Practice Address (Art. 3)	Unique country identifier OPTIONAL (Art. 3)	Donations and Grants to HCOs (Art. 3.01.1.)	Contribution to costs of Events (Art. 3.01.1.b & 3.01.2.a)			Fee for service and consultancy (Art. 3.01.1.c & 3.01.2.c)		TOTAL OPTIONAL	
						Sponsorship agreements with HCOs / third parties appointed by HCOs to manage an Event	Registration Fees	Travel and Accomodation	Fees	Related expenses agreed in the fee for service or consultancy contract, including travel & accommodation relevant to the contract		
INDIVIDUAL NAMED DISCLOSURE - one line per HCP (i.e. all transfers of value during a year for an individual HCP will be summed up: Itemization should be available for the individual Recipient or public authorities' consultation only, as appropriate)												
					N/A	N/A	Yearly amount	Yearly amount	Yearly amount	Yearly amount		
P												
Aggregate amount attributable to transfers of value to such Recipients - Art. 3.02					N/A	N/A	Aggregate HCPs	Aggregate HCPs	34000 NOK	2625 NOK		Optional
Number of Recipients in aggregate disclosure - Art. 3.02					N/A	N/A	Number	Number	4	2		Optional
% of the number of Recipients included in the aggregate disclosure in the total number of Recipients disclosed - Art. 3.02					N/A	N/A	%	%	%	#REF!		N/A
INDIVIDUAL NAMED DISCLOSURE - one line per HCO (i.e. all transfers of value during a year for an individual HCO will be summed up: Itemization should be available for the individual Recipient or public authorities' consultation only, as appropriate)												
NAMED DISCLOSURE - one line per HCO (i.e. all transfers of value during a year for an individual HCO will be summed up: Itemization should be available for the individual Recipient or public authorities' consultation only, as appropriate)												
Sjukehusapoteket i Bergen	Slavanger	Norge				13087 NOK						
Hospital Pharmacy Rikshospitale	Oslo	Norge				9738 NOK						
OTHER, NOT INCLUDED ABOVE - where information cannot be disclosed on an individual basis for legal reasons												
Aggregate amount attributable to transfers of value to such Recipients - Art. 3.02					Aggregate HCOs	Aggregate HCOs	Aggregate HCOs	Aggregate HCOs	Aggregate HCOs	Aggregate HCOs		Optional
Number of Recipients in aggregate disclosure - Art. 3.02					Number	Number	Number	Number	Number	Number		Optional
% of the number of Recipients included in the aggregate disclosure in the total number of Recipients disclosed - Art. 3.02					%	%	%	%	%	%		N/A
Not: N/A												
AGGREGATE DISCLOSURE												
Transfers of Value re Research & Development as defined - Article 3.04 and Schedule 1											34804 NOK	OPTIONAL INFO

With healthcare professional (HCP) refers to a doctor, dentist, pharmacist, nurse or other staff in the health sector who is entitled to prescribe, purchase, supply, recommend or administer medications, including an employee of pharmaceutical companies whose principal employment is in health and health care. Other employees of pharmaceutical companies or pharmaceutical distributor is not covered by the concept of health professionals.

With healthcare (HCO) means any legal entity which operates health care or research or teaching in this area, or is a professional organization with medical or scientific orientation, with the exception of the association referred to in LER Chapter 3.a).

With the transfer of value for research and development provided for distributions to beneficiaries in planning or execution of (i) non-clinical study (defined in the OECD Principles of Good Laboratory Practice), (ii) clinical trial, or (iii) non-interventional study involving collection of patient data from health professionals or on their behalf.